Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Total Debt (2023 - 2025)

Perspective Therapeutics' Total Debt history spans 3 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Total Debt fell 3.36% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, down 3.36%, while the annual FY2024 figure was $1.6 million, 3.04% down from the prior year.
  • Total Debt for Q3 2025 was $1.6 million at Perspective Therapeutics, down from $1.6 million in the prior quarter.
  • Across five years, Total Debt topped out at $1.7 million in Q1 2023 and bottomed at $1.6 million in Q3 2025.
  • The 3-year median for Total Debt is $1.7 million (2024), against an average of $1.6 million.
  • The largest annual shift saw Total Debt fell 2.92% in 2024 before it dropped 3.36% in 2025.
  • A 3-year view of Total Debt shows it stood at $1.7 million in 2023, then dropped by 3.04% to $1.6 million in 2024, then fell by 2.58% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Total Debt are $1.6 million (Q3 2025), $1.6 million (Q2 2025), and $1.6 million (Q1 2025).